Trial Profile
A Randomized, Serum Level-targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Patients With Various Refractory Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Feb 2011
Price :
$35
*
At a glance
- Drugs Gallium maltolate (Primary)
- Indications Bladder cancer; Lymphoma; Multiple myeloma; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Titan Pharmaceuticals
- 04 Feb 2011 New trial record